Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo

Journal of Clinical Investigation

Volumn 108, Issue 4, 2001, Pages 585-590

  Dowd, N P ^a   Scully, M ^a   Adderley, S R ^a   Cunningham, A J ^a   Fitzgerald, D J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ANTHRACYCLINE DERIVATIVE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; ILOPROST; LACTATE DEHYDROGENASE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; THROMBOXANE B2; TRASTUZUMAB; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; HEART INJURY; HEART PROTECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; APOPTOSIS; ARACHIDONIC ACID; ASPIRIN; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOXORUBICIN; ENZYME INDUCTION; EPOPROSTENOL; HEART; ILOPROST; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; MEMBRANE PROTEINS; MYOCARDIUM; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES; THROMBOXANE B2; TRANSCRIPTION FACTORS; TROPONIN T;

EID: 0034894058     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200111334     Document Type: Article

References (36)

1. Doxorubicin-induced cardiomyopathy
2. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity
3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
4. Mitochondrial production of superoxide radical and hydrogen peroxide
5. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation
6. Long-lasting effect of dexrazoxone against anthracycline cardiotoxicity in rats
7. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations
8. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase 2
9. Purification of cyclooxygenase that forms prostaglandins
10. Human cyclooxygenase-2 cDNA
11. Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene
12. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells
13. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor
14. Mol v-src induction of the TIS 10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element
15. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region
16. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA
17. Growth stimulation and induction of epidermal growth factor receptor by over expression of cyclooxygenases 1 and 2 in human colon carcinoma cells
18. Prostaglandin E1 transported into cells blocks the apoptotic signals induced by nerve growth factor deprivation
19. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
20. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
21. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
22. Induction of cyclooxygenase-2 and activation of nuclear factor-kB in myocardium of patients with congestive heart failure
23. Upregulation of COX-2 during cardiac allograft rejection
24. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
25. Pharmacological analysis of cyclooxygenase-1 in inflammation
26. Use off cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity
27. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases
28. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
29. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)
30. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture
31. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2
32. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
33. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
34. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma
35. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system
36. Effect of a prostacyclin derivative (iloprost) on regional blood flow, sympathetic nerve activity, and baroreceptor reflex in the conscious rat